Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: A cross-over study

Thrombosis Research

Volumn 123, Issue 3, 2009, Pages 429-435

  Fleischer, K ^a,c   van Vliet, H A ^a   Rosendaal, F R ^a   Rosing, J ^b   Tchaikovski, S ^b   Helmerhorst, F M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Activated Protein C Resistance; Transdermal Contraceptive Patch; Vaginal Contraceptive Ring

Indexed keywords

ACTIVATED PROTEIN C; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTRACEPTIVE DEVICE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; VAGINA RING; VEIN THROMBOSIS;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; FEMALE; HUMANS; MIDDLE AGED; PROTEIN C; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 57949091395     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.04.022     Document Type: Article

References (24)

1. Gallo M.F., Grimes D.A., and Schulz K.F. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 1 (2003) CD003552
2. van den Heuvel M.W., van Bragt A.J.M., Alnabawy A.K.M., and Kaptein M.C.J. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72 (2005) 168-174
3. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Updat 12 (2006) 169-178
4. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 346 (1995) 1575-1582
5. Jick H., Jick S.S., Gurewich V., Myers M.W., and Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
6. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., Buller H.R., and Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995) 1593-1596
7. Kemmeren J.M., Algra A., and Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 323 (2001) 131-134
8. Cole J.A., Norman H., Doherty M., and Walker A.M. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 109 (2007) 339-346
9. Jick S.S., Kaye J.A., and Russmann S. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinylestradiol. Contraception 73 (2006) 223-228
10. Jick S.S., Kaye J.A., Li L., and Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of contraceptives containing 35 μg ethinyl estradiol. Contraception 76 (2007) 4-7
11. Rosing J., Middeldorp S., Curvers J., Christella M., Thomassen L.G., Nicolaes G.A., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 354 (1999) 2036-2040
12. Tans G., Curvers J., Middeldorp S., Thomassen M.C., Meijers J.C., Prins M.H., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 84 (2000) 15-21
13. Tans G., van Hylckama Vlieg A., Thomassen M.C., Curvers J., Bertina R.M., Rosing J., et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 122 (2003) 465-470
14. Odlind V., Milsom I., Persson I., and Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand 81 (2002) 482-490
15. van Rooijen M., Silveira A., Hamsten A., and Bremme K. Sex hormone-binding globulin-a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 190 (2004) 332-337
16. van Vliet H.A., Frolich M., Christella M., Thomassen L.G., Doggen C.J., Rosendaal F.R., et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 20 (2004) 563-568
17. World Health Organization (1996, 2004). Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. World Health Organization, Geneva. (www.who.int/reproductive-health/publications/mec/).
18. Julious S.A. Sample sizes for clinical trials with Normal data. Statist Med 23 (2004) 1921-1986
19. Rosing J., Tans G., Nicolaes G.A., Thomassen M.C., van Oerle R., van der Ploeg P.M., et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97 (1997) 233-238
20. Kemmeren J.M., Algra A., Meijers J.C., Tans G., Bouma B.N., Curvers J., et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 103 (2004) 927-933
21. Rad M., Kluft C., Menard J., Burggraaf J., de Kam M.L., Meijer P., et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinylestradiol and a combined oral contraceptive containing levonorgestrel on haemostasis variables. Am J Obstet Gynecol 195 (2006) 72-77
22. Hammond G.L., Abrams L.S., Creasy G.W., Natarajan J., Allen J.G., and Siiteri P.K. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 67 (2003) 93-99
23. EMEA. Committee for Proprietary Medicinal Products (CPMP) public assessment report on combined oral contraceptives and venous thromboembolism. (http://www.emea.eu.int/pdfs/human/regaffair/0220101en.pdf).
24. Vasilakis-Scaramozza, and Jick H. Risk of thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358 (2001) 1427-1429